Literature DB >> 27448586

Platelet-Derived Ectosomes Reduce NK Cell Function.

Salima Sadallah1, Laurent Schmied2, Ceylan Eken3, Hojjatollah Nozad Charoudeh2, Francesca Amicarella4, Jürg A Schifferli3.   

Abstract

Platelet (PLT) transfusions are potentially life saving for individuals with low PLT numbers; however, previous work revealed that PLT transfusions are associated with increased infection risk. During storage, PLT intended for transfusion continuously shed ectosomes (Ecto) from their surface, which express immunomodulatory molecules like phosphatidylserine or TGF-β1. Recently, PLT-Ecto were shown to reduce proinflammatory cytokine release by macrophages and to favor the differentiation of naive T cells toward regulatory T cells. Whether PLT-Ecto modify NK cells remains unclear. We exposed purified NK cells and full PBMCs from healthy donors to PLT-Ecto. We found a reduced expression of several activating surface receptors (NKG2D, NKp30, and DNAM-1) and decreased NK cell function, as measured by CD107a expression and IFN-γ production. Pretreatment of PLT-Ecto with anti-TGF-β1 neutralizing Ab restored surface receptor expression and NK cell function. We further observed a TGF-β1-mediated upregulation of miR-183, which, in turn, reduced DAP12, an important protein for stabilization and downstream signaling of several activating NK cell receptors. Again, these effects could antagonized, in part, when PLT-Ecto were preincubated with anti-TGF-β1 Ab. Erythrocyte Ecto did not affect NK cells. Polymorphonuclear cell Ecto expressed MHC class I and inhibited NK cell function. In addition, they induced the secretion of TGF-β1 by NK cells, which participated in an auto/paracrine manner in the suppressive activity of polymorphonuclear cell-derived Ecto. In sum, our study showed that PLT-Ecto could inhibit NK cell effector function in a TGF-β1-dependent manner, suggesting that recipients of PLT transfusions may experience reduced NK cell function.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27448586     DOI: 10.4049/jimmunol.1502658

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  TGFβ biology in cancer progression and immunotherapy.

Authors:  Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal:  Nat Rev Clin Oncol       Date:  2020-07-24       Impact factor: 66.675

2.  Blood manufacturing methods affect red blood cell product characteristics and immunomodulatory activity.

Authors:  Ruqayyah J Almizraq; Philip J Norris; Heather Inglis; Somaang Menocha; Mathijs R Wirtz; Nicole Juffermans; Suchitra Pandey; Philip C Spinella; Jason P Acker; Jennifer A Muszynski
Journal:  Blood Adv       Date:  2018-09-25

3.  Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer.

Authors:  Yan Xia; Xin Lin; Yangyang Cheng; Huimin Xu; Jingya Zeng; Wanlin Xie; Mingzhu Wang; Yihua Sun
Journal:  Front Genet       Date:  2022-06-28       Impact factor: 4.772

Review 4.  Insights Into Platelet-Derived MicroRNAs in Cardiovascular and Oncologic Diseases: Potential Predictor and Therapeutic Target.

Authors:  Qianru Leng; Jie Ding; Meiyan Dai; Lei Liu; Qing Fang; Dao Wen Wang; Lujin Wu; Yan Wang
Journal:  Front Cardiovasc Med       Date:  2022-06-09

Review 5.  Mechanisms of red blood cell transfusion-related immunomodulation.

Authors:  Kenneth E Remy; Mark W Hall; Jill Cholette; Nicole P Juffermans; Kathleen Nicol; Allan Doctor; Neil Blumberg; Philip C Spinella; Philip J Norris; Mary K Dahmer; Jennifer A Muszynski
Journal:  Transfusion       Date:  2018-01-30       Impact factor: 3.157

6.  Metabolomics and Proteomics Reveal the Variation of Substances in Apheresis Platelets during Storage and Their Effects on Cancer Cell Proliferation.

Authors:  Xiaofei Li; Yuan Zhang; Fu Cheng; Yang Yu; Deqing Wang
Journal:  Transfus Med Hemother       Date:  2020-09-25       Impact factor: 3.747

Review 7.  Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment.

Authors:  Ze-Long Liu; Jing-Hua Liu; Daniel Staiculescu; Jiang Chen
Journal:  Ther Adv Med Oncol       Date:  2021-05-24       Impact factor: 8.168

8.  Functional visualization of NK cell-mediated killing of metastatic single tumor cells.

Authors:  Hiroshi Ichise; Shoko Tsukamoto; Tsuyoshi Hirashima; Yoshinobu Konishi; Choji Oki; Shinya Tsukiji; Satoshi Iwano; Atsushi Miyawaki; Kenta Sumiyama; Kenta Terai; Michiyuki Matsuda
Journal:  Elife       Date:  2022-02-03       Impact factor: 8.140

Review 9.  Platelets and viruses.

Authors:  Silvio Antoniak; Nigel Mackman
Journal:  Platelets       Date:  2021-02-22       Impact factor: 3.862

10.  Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL).

Authors:  Andrea Sitlinger; Michael A Deal; Erwin Garcia; Dana K Thompson; Tiffany Stewart; Grace A MacDonald; Nicolas Devos; David Corcoran; Janet S Staats; Jennifer Enzor; Kent J Weinhold; Danielle M Brander; J Brice Weinberg; David B Bartlett
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.